Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Study confirms genetic differences in breast tissue among races

AACR 2011

Published: 15 Apr 2011

Views: 5200

Rating:

Save

Dr Lisa Baumbach - University of Miami Miller School of Medicine, USA

Scientists from Sylvester Comprehensive Cancer Center are working on a series of genetic analyses that suggest the underlying differences among racial groups are present not just in tumours, but in normal tissue as well. Dr Baumbach’s research group is observing a multi-ethnic cohort of patients with triple-negative breast cancer. Results showed that the number of genes related to the DNA repair pathway was expressed differently across ethnicities. In a set of 10 DNA repair/cell cycle genes, the direction of change was the same for all three ethnic groups, but the level of change differed.

Categories:
Breast
Biology

Related Videos

Post-diagnosis diet, nutrition and cancer prognosis

Dr Doris Chan - Imperial College London, London, UK

Post-diagnosis diet, nutrition and cancer prognosis ( Dr Doris Chan - Imperial College London, London, UK )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Breastfeeding after breast cancer is safe

Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy

Breastfeeding after breast cancer is safe ( Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy

Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy ( Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines )

More from ecancer